NRX Pharmaceuticals Board Changes and Officer Compensation
Ticker: NRXPW · Form: 8-K · Filed: Aug 20, 2024 · CIK: 1719406
| Field | Detail |
|---|---|
| Company | Nrx Pharmaceuticals, INC. (NRXPW) |
| Form Type | 8-K |
| Filed Date | Aug 20, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-change, executive-compensation
Related Tickers: NRXP
TL;DR
Rothbard out at NRXP, board shakeup and exec pay details.
AI Summary
NRX Pharmaceuticals, Inc. announced on August 14, 2024, a change in its board of directors. Specifically, Dr. Jonathan Rothbard resigned from the Board of Directors, effective immediately. The company also disclosed compensatory arrangements for certain officers.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, while details on officer compensation are relevant to shareholder interests and executive accountability.
Risk Assessment
Risk Level: medium — Board changes and executive compensation disclosures can sometimes precede or accompany significant strategic shifts or financial events, warranting closer attention.
Key Players & Entities
- NRX Pharmaceuticals, Inc. (company) — Registrant
- Dr. Jonathan Rothbard (person) — Resigned Director
- August 14, 2024 (date) — Effective date of resignation
FAQ
Who replaced Dr. Jonathan Rothbard on the Board of Directors?
The filing does not specify who, if anyone, replaced Dr. Jonathan Rothbard on the Board of Directors.
What was the stated reason for Dr. Rothbard's resignation?
The filing states Dr. Rothbard's resignation was effective immediately, but does not provide a specific reason.
When was Dr. Rothbard's resignation effective?
Dr. Rothbard's resignation was effective on August 14, 2024.
Does this filing detail any new compensatory arrangements for officers?
Yes, the filing indicates that compensatory arrangements of certain officers are being disclosed.
What is the company's fiscal year end?
The company's fiscal year end is December 31.
Filing Stats: 511 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-08-20 16:38:59
Key Financial Figures
- $0.001 — registered Common Stock , par value $0.001 per share NRXP The Nasdaq Stock Mark
Filing Documents
- nrxp20240820_8k.htm (8-K) — 24KB
- 0001437749-24-027383.txt ( ) — 172KB
- nxrp-20240814.xsd (EX-101.SCH) — 4KB
- nxrp-20240814_def.xml (EX-101.DEF) — 13KB
- nxrp-20240814_lab.xml (EX-101.LAB) — 18KB
- nxrp-20240814_pre.xml (EX-101.PRE) — 14KB
- nrxp20240820_8k_htm.xml (XML) — 5KB
01. Other Events
Item 8.01. Other Events See Item 5.02 above.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NRX PHARMACEUTICALS, INC. Date: August 20, 2024 By: /s/ Jonathan Javitt Name: Jonathan Javitt Title: Chairman of the Board of Directors